- Email: [email protected]
ANTIHYPERGLYCEMIC AND ANTIHYPERLIPIDEMIC EFFECTS OF MNGIFERA INDICA L. IN STREPTOZOCINE INDUCED DIABETIC RATS
206
Poster Sessions PO49 Therapeutic interventions – other
tional statin treatment. Therefore it is important that clinicians carefully monitor the effect on LDL-C on given therapy and adjust choice of statin and dose accordingly. PO48-760
COST-EFFECTIVENESS OF AGGRESSIVE LDL-C LOWERING FOR ACUTE CORONARY SYNDROM PATIENTS IN FRANCE
G. de Pouvourville 1 , B. Gueron 2 , A. Solesse de Gendre 3 . 1 Chair of Health Economics, Essec, France; 2 Outcome Research, Pfizer, Paris, France; 3 Outcome Research, Pfizer, France Background and aims: The PROVE-IT TIMI2 trial has demonstrated the benefits of aggressive LDL-C lowering with high dose atorvastatin (80 mg per day) compared to generic pravastatin (40 mg per day) to prevent death or major cardiovascular events in patients with acute coronary syndrome (ACS). The study measured the incremental cost-per-life year saved of the stategy in the French context. Method: A model was developed based on the clinical results of the PROVE-IT trial and on Framingham predictive equations of survival after cardiovascular events. Direct medical costs per event were considered, using data from the French National Cost per Stay survey, providing full costs for public hospitals. Results: The daily cost of treatment with atorvastatin was 1.54 € vs 0.94€ for pravastatin. The total average cost per patient over two years in the atorvastatin group was 3,471 € vs 3,543 € in the pravastatin group. The incremental number of life-years saved per patient was 0.092, or 1.11 months. High dose atorvastatin was cost-saving. With a 20% reduction in the effectiveness of prevention in both groups due to compliance, an extra cost of 80 € was observed with atorvastatin, leading to an incremental cost-per-life year saved of 1,075 € per year. Conclusion: Aggressive lowering of LDL-C for ACS patients is effective in preventing deaths and severe cardio-vascular events and can be cost-saving. Identical results were found in the USA, with a high cost saving of $ 1,612 per patient when atorvastatin was compared to a generic statin.
PO49 THERAPEUTIC INTERVENTIONS – OTHER PO49-761
ANTIHYPERGLYCEMIC AND ANTIHYPERLIPIDEMIC EFFECTS OF MNGIFERA INDICA L. IN STREPTOZOCINE INDUCED DIABETIC RATS
J. Solati. Microbiology department, Islamic azad university-karaj branch, Karaj,Tehran,Iran Herbal medicine and medical plants such as Mangifera indica L. widely used for treatment of disease like diabetes mellitus. we investigated effects of water extracts of Mangifera indica L. on serum glucose, triglycerides, cholesterol, LDL, HDL and activities of aminotransferase enzymes in streptozocin-induced diabetic adult male rats. Continuous supplementation of this water extract by gavage at dose of 0.2, 0.5 and 1 g/kg at 0.5ml distilled water in diabetic rats result a significant diminution of fasting blood glucose and triglycerides level after 14 days. Levels of LDL, HDL and activities of serum aminotransaminase enzymes, alanine aminotransferase (ALT) and aspartate aminotransferase (AST), were changed not significantly in the extract supplemented group in respect to control group. PO49-762
DIETARY PHYTOSTEROLS REDUCE PLASMA ENDOTHELIN IN MODERATELY PRIMARY HYPERCHOLESTEROLEMIA
A. Ilha, E. Nakandakare, V. Nunes, E. Quintao, A. Lottenberg. Lipids Laboratory LIM-10, Faculty of Medical Sciences of University of São Paulo, Brazil Background and aims: Phytosterols (PS) in alimentary products have been shown to lower plasma total cholesterol (TC) and LDL-C concentrations in humans and animals but the PS effect on inflammatory and other biomarkers of atherosclerosis has not been fully investigated. To investigate the effects of the soy milk enriched with PS on blood lipid profile and on markers of atherosclerosis in moderately hypercholesterolemic subjects.
Methods: Moderately hypercholesterolemia patients (n=38, mean ± plasma cholesterol 245±34 mg/dL, and age 58±8 y) were recruited at the Clinical Hospital, FMUSP. They consumed 400 mL of soy milk for 8 wk; being 4 wk enriched with PS (1.6 g/day) and 4 wk on placebo, in a randomized, cross-over study. Individuals were advised to maintain their regular diet and physical activity. Blood samples were drawn after an overnight fasting period at the end of each phase. Results: Body weight did not change over the study period. PS reduced plasma lipids: TC 5.5% (P<0.001), LDL-chol 6.4% and TG by 8.3% (P<0.05). HDL-c levels were not modified. TNFα, interleukin-6, hsCRP, amyloid A, were not modified but endothelin-1 (ET-1, pg/mL±SD) decreased from 5.20±1.71 to 4.56±1.79 (p=0.02) on PS. Conclusion: Soy milk enriched with PS is effective in improving lipid profiles in hyperchosterolemic subjects and in addition lowers plasma ET-1. PO49-763
THE EFFECT OF NANDROLONE DECANOATE THERAPY ON LIPOPROTEIN(A) AND HOMOCYSTEINE LEVELS IN HEMODIALYSIS PATIENTS
N. Rashtchizadeh, A. Ghorbanihaghjo, H. Argani, M. Rohbaninoubar, A. Vatankhah, M. Mesgari, A. Daneshvar. Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran Lipoprotein(a) [Lp(a)] and Homocysteine (Hcy) are two independent risk factors for atherogenicity in patients with chronic renal failure (CRF). It has been postulated that Hcy can enhance the toxicity of Lp(a) via binding to fibrin. As Nandrolone Decanoate (ND), an anabolic steroid, reduces Lp(a) in CRF this study was designed to evaluate the influence of the drug on serum total Hcy (tHcy) in addition of Lp(a) levels and their relationships in 64 chronic hemodialysis patients. The patients received 100mg/I.M./week for 4 months to improve their anemia. Serum Lp(a) concentrations were determined by immunoturbidimetric method, and tHcy levels were measured by enzyme-linked immunosorbent assay. Although marked decrease in Lp(a) levels was observed (40.6±24mg/dl reached to 31.3±17.2mg/dl p<0.0001) tHcy concentration did not change significantly (18.4±8.2 mol/L reached to 19.2±7.2 mol/L p>0.1). Therefore tHcy/Lp(a) ratio (0.67±0.5 vs. 0.86±0.7 p<0.0001) increased. It was concluded that ND has beneficial effect on lowering serum level of Lp(a). Because of nearly constant level of tHcy and elevation in tHcy/Lp(a) ratio after ND therapy, Lp(a) lowering effect of ND therapy alone may have limited contribution in prevention of atherosclerosis PO49-764
PHYTOSTEROLS EFFECTS IN LIPID PROFILE OF PATIENTS WITH MILD HYPERLIPEMIA
C. Banuls-Morant, A. Lopez-Ruiz, M. Martinez-Triguero, C. Morillas-Arino, K. Garcia-Malpartida, A. Hernandez-Mijares. Endocrinology, Lipids and Metabolism Unit. University Hospital Doctor Peset. Valencia. Spain Background and aims: It is known for a long time that phytosterols, vegetal analogs of the cholesterol, can have a hypolipemiant effect. The objective of our study is to evaluate their effect in patients with mild hyperlipemia in relation with lipid profile and size of LDL. Methods: We have studied 93 hyperlipemic patients, 27 men and 66 women, with the criteria: cLDL >160 mg/dL, cLDL >130 mg/dL and 2 or more cardiovascular risk factors and in secondary prevention LDLc between 100 and 130 mg/dL. The study consisted in administering a standard diet until the end of the study. At 3 months the patients were randomized 1:1; a part continued only with diet and the others with diet and 2 g of phytosterols (in milky compound form). We measured: total cholesterol and triglycerid by enzymatic method, LDLc by Friedewald’s formula, Apo B by inmunonefelometry and the size of LDL by PAGE. Results: Phytosterols has been well tolerated by the patients. It has been observed a decrease of 9.8% in total cholesterol in patients with phytosterols (vs. 6.7%) and a decrease of 11.6% in LDLc (vs. 8.2%). Variations in the size of LDL have not been observed. Conclusions: The reduction observed in total cholesterol, LDLc, nonHDLc and Apo B in patients with mild hypercolesterolemia treated with phytosterols, make phytosterols a useful initial treatment. Variations in the size of LDL have not been observed, as in patients where there is no hypertriglyceridemia or it has not been observed significant reductions on triglycerids.
77th Congress of the European Atherosclerosis Society, April 26–29, 2008, Istanbul, Turkey
Poster Sessions PO49 Therapeutic interventions – other
tional statin treatment. Therefore it is important that clinicians carefully monitor the effect on LDL-C on given therapy and adjust choice of statin and dose accordingly. PO48-760
COST-EFFECTIVENESS OF AGGRESSIVE LDL-C LOWERING FOR ACUTE CORONARY SYNDROM PATIENTS IN FRANCE
G. de Pouvourville 1 , B. Gueron 2 , A. Solesse de Gendre 3 . 1 Chair of Health Economics, Essec, France; 2 Outcome Research, Pfizer, Paris, France; 3 Outcome Research, Pfizer, France Background and aims: The PROVE-IT TIMI2 trial has demonstrated the benefits of aggressive LDL-C lowering with high dose atorvastatin (80 mg per day) compared to generic pravastatin (40 mg per day) to prevent death or major cardiovascular events in patients with acute coronary syndrome (ACS). The study measured the incremental cost-per-life year saved of the stategy in the French context. Method: A model was developed based on the clinical results of the PROVE-IT trial and on Framingham predictive equations of survival after cardiovascular events. Direct medical costs per event were considered, using data from the French National Cost per Stay survey, providing full costs for public hospitals. Results: The daily cost of treatment with atorvastatin was 1.54 € vs 0.94€ for pravastatin. The total average cost per patient over two years in the atorvastatin group was 3,471 € vs 3,543 € in the pravastatin group. The incremental number of life-years saved per patient was 0.092, or 1.11 months. High dose atorvastatin was cost-saving. With a 20% reduction in the effectiveness of prevention in both groups due to compliance, an extra cost of 80 € was observed with atorvastatin, leading to an incremental cost-per-life year saved of 1,075 € per year. Conclusion: Aggressive lowering of LDL-C for ACS patients is effective in preventing deaths and severe cardio-vascular events and can be cost-saving. Identical results were found in the USA, with a high cost saving of $ 1,612 per patient when atorvastatin was compared to a generic statin.
PO49 THERAPEUTIC INTERVENTIONS – OTHER PO49-761
ANTIHYPERGLYCEMIC AND ANTIHYPERLIPIDEMIC EFFECTS OF MNGIFERA INDICA L. IN STREPTOZOCINE INDUCED DIABETIC RATS
J. Solati. Microbiology department, Islamic azad university-karaj branch, Karaj,Tehran,Iran Herbal medicine and medical plants such as Mangifera indica L. widely used for treatment of disease like diabetes mellitus. we investigated effects of water extracts of Mangifera indica L. on serum glucose, triglycerides, cholesterol, LDL, HDL and activities of aminotransferase enzymes in streptozocin-induced diabetic adult male rats. Continuous supplementation of this water extract by gavage at dose of 0.2, 0.5 and 1 g/kg at 0.5ml distilled water in diabetic rats result a significant diminution of fasting blood glucose and triglycerides level after 14 days. Levels of LDL, HDL and activities of serum aminotransaminase enzymes, alanine aminotransferase (ALT) and aspartate aminotransferase (AST), were changed not significantly in the extract supplemented group in respect to control group. PO49-762
DIETARY PHYTOSTEROLS REDUCE PLASMA ENDOTHELIN IN MODERATELY PRIMARY HYPERCHOLESTEROLEMIA
A. Ilha, E. Nakandakare, V. Nunes, E. Quintao, A. Lottenberg. Lipids Laboratory LIM-10, Faculty of Medical Sciences of University of São Paulo, Brazil Background and aims: Phytosterols (PS) in alimentary products have been shown to lower plasma total cholesterol (TC) and LDL-C concentrations in humans and animals but the PS effect on inflammatory and other biomarkers of atherosclerosis has not been fully investigated. To investigate the effects of the soy milk enriched with PS on blood lipid profile and on markers of atherosclerosis in moderately hypercholesterolemic subjects.
Methods: Moderately hypercholesterolemia patients (n=38, mean ± plasma cholesterol 245±34 mg/dL, and age 58±8 y) were recruited at the Clinical Hospital, FMUSP. They consumed 400 mL of soy milk for 8 wk; being 4 wk enriched with PS (1.6 g/day) and 4 wk on placebo, in a randomized, cross-over study. Individuals were advised to maintain their regular diet and physical activity. Blood samples were drawn after an overnight fasting period at the end of each phase. Results: Body weight did not change over the study period. PS reduced plasma lipids: TC 5.5% (P<0.001), LDL-chol 6.4% and TG by 8.3% (P<0.05). HDL-c levels were not modified. TNFα, interleukin-6, hsCRP, amyloid A, were not modified but endothelin-1 (ET-1, pg/mL±SD) decreased from 5.20±1.71 to 4.56±1.79 (p=0.02) on PS. Conclusion: Soy milk enriched with PS is effective in improving lipid profiles in hyperchosterolemic subjects and in addition lowers plasma ET-1. PO49-763
THE EFFECT OF NANDROLONE DECANOATE THERAPY ON LIPOPROTEIN(A) AND HOMOCYSTEINE LEVELS IN HEMODIALYSIS PATIENTS
N. Rashtchizadeh, A. Ghorbanihaghjo, H. Argani, M. Rohbaninoubar, A. Vatankhah, M. Mesgari, A. Daneshvar. Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran Lipoprotein(a) [Lp(a)] and Homocysteine (Hcy) are two independent risk factors for atherogenicity in patients with chronic renal failure (CRF). It has been postulated that Hcy can enhance the toxicity of Lp(a) via binding to fibrin. As Nandrolone Decanoate (ND), an anabolic steroid, reduces Lp(a) in CRF this study was designed to evaluate the influence of the drug on serum total Hcy (tHcy) in addition of Lp(a) levels and their relationships in 64 chronic hemodialysis patients. The patients received 100mg/I.M./week for 4 months to improve their anemia. Serum Lp(a) concentrations were determined by immunoturbidimetric method, and tHcy levels were measured by enzyme-linked immunosorbent assay. Although marked decrease in Lp(a) levels was observed (40.6±24mg/dl reached to 31.3±17.2mg/dl p<0.0001) tHcy concentration did not change significantly (18.4±8.2 mol/L reached to 19.2±7.2 mol/L p>0.1). Therefore tHcy/Lp(a) ratio (0.67±0.5 vs. 0.86±0.7 p<0.0001) increased. It was concluded that ND has beneficial effect on lowering serum level of Lp(a). Because of nearly constant level of tHcy and elevation in tHcy/Lp(a) ratio after ND therapy, Lp(a) lowering effect of ND therapy alone may have limited contribution in prevention of atherosclerosis PO49-764
PHYTOSTEROLS EFFECTS IN LIPID PROFILE OF PATIENTS WITH MILD HYPERLIPEMIA
C. Banuls-Morant, A. Lopez-Ruiz, M. Martinez-Triguero, C. Morillas-Arino, K. Garcia-Malpartida, A. Hernandez-Mijares. Endocrinology, Lipids and Metabolism Unit. University Hospital Doctor Peset. Valencia. Spain Background and aims: It is known for a long time that phytosterols, vegetal analogs of the cholesterol, can have a hypolipemiant effect. The objective of our study is to evaluate their effect in patients with mild hyperlipemia in relation with lipid profile and size of LDL. Methods: We have studied 93 hyperlipemic patients, 27 men and 66 women, with the criteria: cLDL >160 mg/dL, cLDL >130 mg/dL and 2 or more cardiovascular risk factors and in secondary prevention LDLc between 100 and 130 mg/dL. The study consisted in administering a standard diet until the end of the study. At 3 months the patients were randomized 1:1; a part continued only with diet and the others with diet and 2 g of phytosterols (in milky compound form). We measured: total cholesterol and triglycerid by enzymatic method, LDLc by Friedewald’s formula, Apo B by inmunonefelometry and the size of LDL by PAGE. Results: Phytosterols has been well tolerated by the patients. It has been observed a decrease of 9.8% in total cholesterol in patients with phytosterols (vs. 6.7%) and a decrease of 11.6% in LDLc (vs. 8.2%). Variations in the size of LDL have not been observed. Conclusions: The reduction observed in total cholesterol, LDLc, nonHDLc and Apo B in patients with mild hypercolesterolemia treated with phytosterols, make phytosterols a useful initial treatment. Variations in the size of LDL have not been observed, as in patients where there is no hypertriglyceridemia or it has not been observed significant reductions on triglycerids.
77th Congress of the European Atherosclerosis Society, April 26–29, 2008, Istanbul, Turkey